Fast track your drug development programs with Syngene

Preclinical to commercial

Syngene International, a global integrated research, development, and manufacturing services company, will be exhibiting at CPHI Worldwide 2024, Milan, Booth #7C114, from October 8-10.   

With more than three decades of experience, 400+ active global clients, and 400+ patents held with clients, Syngene offers end-to-end services from preclinical to commercial across modalities.

What makes Syngene the preferred CRO-CDMO partner

India advantage

Headquartered in India, we offer the benefits of cost-efficiency and supply stability. We have a network of 2500+ suppliers spread across 30+ countries, flexible manufacturing capacity, and world-class scientists to support your R&D programs.

End-to-end services

Our scientific solutions are across therapeutic areas and modalities, including small molecules, biologics, oligonucleotides, and peptides.  

Manufacturing capacity

We offer flexible manufacturing capacity, including custom manufacturing from our USFDA, and EMA-approved facilities – 70,000L for small molecules and 28,000L (expandible to 48,000L) for biologics. We also have a high-speed fill-finish facility with a capacity of 1 million vials/day.

Biologics expertise

Our ongoing expansion in capabilities and capacity in Biologics has established Syngene as one of the largest CRDMOs in India. As a trusted partner, we have delivered 100 commercial batches in the last two years. Our track record of over 250 GMP batches, 150+ projects, and support for over 25 INDs across biologics modalities demonstrates our expertise.

Sustainability

Our continuous commitment to excellence in environmental, social, and governance (ESG) practices has resulted in the company securing a silver rating in the prestigious EcoVadis sustainability index for FY2024, placing us among the top 15% of companies assessed worldwide.

Co​​​​​​​ntact us

To book a meeting with our experts, visit: www.syngeneintl.com/contact-us

Go to article: Home | Cell and gene therapy approvals drive paradigm change in manufacturingGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: Syngene Company InsightGo to article: SyngeneGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: PCI Pharma ServicesGo to article: AlfatestLAB - CPHIGo to article: RHEACELL Company InsightGo to article: In DepthGo to article: Cell and gene therapy approvals drive paradigm change in manufacturingGo to article: After the Lykos debacle, what’s next for psychedelic therapies?Go to article: Compounding pharmacies caught in counterfeit controversyGo to article: How the Covid-19 pandemic will help researchers with the mpox emergencyGo to article: Iterum’s oral sulopenem acceptance hinges on antibiotic stewardship effortsGo to article: Clinical research in the UK must build on industry collaboration, says NIHR directorGo to article: Keytruda and Opdivo: a decade reviewGo to article: Alphial - CPHIGo to article: RephineGo to article: Rephine - CPHIGo to article: Thematic Take: AIGo to article: Thematic Take: contentsGo to article: Foreword: Generative AI as a force of creative destructionGo to article: The road to advanced AI capabilitiesGo to article: AI technology: Market size and growth forecasts Go to article: Timeline: a history of AIGo to article: The impact of AI on the pharma sectorGo to article: Case studies: AI in pharmaGo to article: Latest news: AI in pharmaGo to article: AI boom set to revolutionise healthcare in EuropeGo to article: How NVIDIA grew with the healthcare market instead of pushing into itGo to article: Capturing the genAI boom for drug developmentGo to article: New AI model boosts early osteoporosis diagnosis for ageing populationsGo to article: Impact of AI on metabolic disorder clinical trialsGo to article: Resist temptation to rapidly roll out AI – executives must focus on talent and trainingGo to article: Is AI really helping employees?Go to article: Is your business ready for the rise of AI agents?Go to article: Deal activity related to AI in the pharma industry since 2021Go to article: Sponsored SupplementsGo to article: BEA TechnologiesGo to article: Techniconsult Firenze - CPHIGo to article: Science4TechGo to article: ListingsGo to article: EventsGo to article: Excellence AwardsGo to article: Innovation RankingsGo to article: Buyer's GuidesGo to article: Next issue